Published in PLoS One on December 31, 2013
Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays. Cells (2014) 0.86
Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis (2015) 0.81
Waning and aging of cellular immunity to Bordetella pertussis. Pathog Dis (2015) 0.81
Th1 versus Th2 T cell polarization by whole-cell and acellular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cell Immunol (2016) 0.79
The Use of Innovative Two-Component Cluster Analysis and Serodiagnostic Cut-Off Methods to Estimate Prevalence of Pertussis Reinfections. PLoS One (2016) 0.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02
ProPred: prediction of HLA-DR binding sites. Bioinformatics (2001) 4.39
Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis (1999) 3.48
TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 3.44
Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J (2005) 3.14
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 3.10
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 3.07
Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol (2006) 3.03
Recent developments in pertussis. Lancet (2006) 2.79
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun (1993) 2.36
Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis (1997) 2.32
Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol (2012) 2.09
Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol (2005) 2.04
Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun (1997) 2.03
Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol (2005) 2.01
Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell (1997) 1.93
The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88
Immunity to Bordetella pertussis. Microbes Infect (2001) 1.86
Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis (2000) 1.85
First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine (2009) 1.84
Pertussis in Quebec: ongoing epidemic since the late 1980s. Can Commun Dis Rep (1995) 1.81
Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med (1997) 1.81
Return of epidemic pertussis in the United States. Pediatr Infect Dis J (1994) 1.77
Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology (1998) 1.75
Pertussis in Poland. Int J Epidemiol (2004) 1.64
Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 1.59
Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med (2000) 1.55
Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One (2012) 1.52
Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol (2003) 1.52
Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med (1989) 1.49
Factors contributing to pertussis resurgence. Future Microbiol (2008) 1.35
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect Immun (1991) 1.31
A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods (2003) 1.29
Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis (2000) 1.17
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev (2002) 1.04
T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin Vaccine Immunol (2012) 0.94
Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun (2001) 0.93
Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination. Clin Exp Immunol (2012) 0.92
Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One (2012) 0.91
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Memory in disguise. Nat Med (2011) 0.89
Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol (2009) 0.87
Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin Diagn Lab Immunol (1999) 0.83
Antigen-specific responses assessment for the evaluation of Bordetella pertussis T cell immunity in humans. Vaccine (2012) 0.83
Detection of cellular immunity to rabies antigens in human vaccinees. J Clin Immunol (2006) 0.81
A genomics-based approach to assessment of vaccine safety and immunogenicity in children. Vaccine (2012) 0.80
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One (2015) 0.85
Age related differences in dynamics of specific memory B cell populations after clinical pertussis infection. PLoS One (2014) 0.77
Vaccine-Mediated Activation of Human TLR4 Is Affected by Modulation of Culture Conditions during Whole-Cell Pertussis Vaccine Preparation. PLoS One (2016) 0.75
Hb Boskoop [HBA2c.112C>T p.Pro38Ser]: a new α2 chain variant observed in a Morrocan family. Hemoglobin (2011) 0.75